# Bruxism Xeomin® Intervention Trial

> **NCT04792398** · PHASE4 · UNKNOWN · sponsor: **Dominik Ettlin** · enrollment: 6 (estimated)

## Conditions studied

- Sleep Bruxism, Adult

## Interventions

- **DRUG:** Incobotulinumtoxin A (BTX A) Xeomin®

## Key facts

- **NCT ID:** NCT04792398
- **Lead sponsor:** Dominik Ettlin
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2021-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04792398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04792398, "Bruxism Xeomin® Intervention Trial". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04792398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*